Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Animal model for testing osteoporotic therapies available for licensing

Nov. 29, 1996

rhBMP-2 cleared for limited clinical trial for spine fusion

Nov. 28, 1996

FDA clears treatment for bulimia

Nov. 27, 1996

Water-soluble fiber introduced in first market for high cholesterol

Nov. 27, 1996

Agreement reached for atorvastatin development in Japan

Nov. 27, 1996

Uropontin and MAbs with potential in osteoporosis available for licensing

Nov. 26, 1996

Somatogen reports plans for Optro

Nov. 26, 1996

Milestone achieved in Millennium/Roche research collaboration

Nov. 25, 1996

Research suggests improved treatment for anemia

Nov. 25, 1996

Zonagen allowed further patent coverage for zona pellucida proteins

Nov. 25, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...